{"abstract": "Global sales of Sovaldi brought it close to being the best-selling drug in the world in only its first year on the market.", "web_url": "https://www.nytimes.com/2015/02/04/business/sales-of-sovaldi-new-gilead-hepatitis-c-drug-soar-to-10-3-billion.html", "snippet": "Global sales of Sovaldi brought it close to being the best-selling drug in the world in only its first year on the market.", "lead_paragraph": "Gilead Sciences sold $10.3 billion of its new hepatitis C drug Sovaldi in 2014, a figure that brought it close to being the best-selling drug in the world in only its first year on the market. ", "print_section": "B", "print_page": "2", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/04/business/04GILEAD/04GILEAD-articleLarge.jpg", "height": 567, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/02/04/business/04GILEAD/04GILEAD-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 567}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/04/business/04GILEAD/04GILEAD-jumbo.jpg", "height": 968, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/04/business/04GILEAD/04GILEAD-superJumbo.jpg", "height": 1937, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/04/business/04GILEAD/04GILEAD-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/02/04/business/04GILEAD/04GILEAD-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/04/business/04GILEAD/04GILEAD-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion", "kicker": null, "content_kicker": null, "print_headline": "Sales of New Hepatitis C Drug Soar to $10.3 Billion, Straining Budgets", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Gilead Sciences Inc", "rank": 1, "major": "N"}, {"name": "persons", "value": "Pollack, Andrew", "rank": 2, "major": "N"}, {"name": "subject", "value": "Sovaldi (Drug)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Hepatitis", "rank": 4, "major": "N"}, {"name": "subject", "value": "Company Reports", "rank": 5, "major": "N"}, {"name": "subject", "value": "Harvoni (Drug)", "rank": 6, "major": "N"}], "pub_date": "2015-02-03T23:22:03+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/75e5d4bb-a99f-534e-b7df-e68c179aeeba", "word_count": 913, "uri": "nyt://article/75e5d4bb-a99f-534e-b7df-e68c179aeeba"}